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Abstract
Objective: This study examined the role of lithium in the maintenance treatment of pediatric 
patients with bipolar I disorder (BP-I).
Method: Participants, aged 7 to 17 years presenting with a manic or mixed episode, received 24 
weeks of lithium treatment in one of two multiphase studies, the Collaborative Lithium Trials 
(CoLT 1 and CoLT 2). Responders were randomized to continue lithium or to be cross titrated to 
placebo for up to 28 weeks. The primary outcome measure was relative risk of study 
discontinuation for any reason.
Results: A Cox regression analysis found that those who continued treatment with lithium 
(n=17) had a lower hazard ratio compared to those who received placebo [n=14 (p=0.015)]. The 
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vast majority of discontinuations were due to mood symptom exacerbations, with most of these 
occurring in the placebo-treated group. Discontinuation for other reasons occurred at similarly low 
rates across both group. Most adverse events were mild to moderate in severity, and only one study 
participant was discontinued from the trial owing to a serious adverse event (aggression). There 
was no statistically significant difference with respect to weight gain in participants receiving 
lithium compared to those receiving placebo.
Conclusion: This randomized, double-blind, placebo-controlled discontinuation trial builds 
support for the role of lithium as a maintenance treatment in pediatric patients with bipolar 
disorder and for the safety and tolerability of 28 weeks of maintenance lithium treatment.
Keywords
lithium; bipolar; treatment; adolescents; children
Introduction
Bipolar disorder in children and adolescents is associated with significant long-term 
morbidity and disability.1-4 Owing to the severity and persistence of bipolar disorder into 
adulthood,5-9 safe and effective long-term treatments are needed.
Placebo-controlled studies to date suggest that quetiapine, risperidone, olanzapine, 
aripiprazole, ziprasidone, and asenapine may have a role in the treatment of acute mania in 
pediatric patients.10-15 Despite lithium’s history as an established benchmark treatment for 
adults with bipolar disorder in adults,16-20 double-blind, placebo-controlled data for children 
have historically been lacking. A recent double-blind, placebo-controlled study from our 
group showed lithium’s efficacy and effect size in the acute treatment of mania in pediatric 
patients is comparable to what has been reported in adult patients.21 Recent open-label data 
that we have published also indicate that lithium may be a safe and effective longer-term 
treatment for pediatric patients with bipolar disorder who respond to acute treatment with 
lithium.22
There are limited prospective long-term pharmacological treatment data for bipolar disorder 
in children and adolescents. Previous prospective data in the pediatric age group have 
generally been restricted to combination pharmacotherapy studies.23-25 In addition, 
aripiprazole has been found to be superior to placebo in the post-acute treatment of children 
and adolescents with bipolar disorder.26,27 However, only a modest amount of information 
exists based on double-blind, placebo-controlled data regarding the treatment of pediatric 
patients with lithium beyond eight weeks.28 The purpose of this study is to examine the role 
of lithium in the maintenance treatment of pediatric patients with bipolar I disorder.
Method
This work was sponsored by the Eunice Kennedy Shriver National Institute of Child Health 
and Human Development (NICHD) “Best Pharmaceuticals for Children Act Pediatric Off-
Patent Drug Study (PODS): Lithium in the Treatment of Pediatric Mania” (Contract 
HHSN275200503406C).
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Institutional Review Board (IRB) approval of the protocol, informed consent, advertising 
and all amendments were obtained prior to implementation at all study locations. Prior to the 
initiation of any study-related procedures, the informed consent statement was signed by the 
participant’s parent or legal guardian and by the person who was authorized to administer 
the informed consent. Further, children who could read and understand the assent form were 
asked to give written assent.
This work was a multi-center, double-blind, placebo-controlled study. All study participants 
included in this Discontinuation Trial received 24 weeks of open-label lithium prior to study 
entry. Most participants (n=21) entered from CoLT 1,22,29 after completing 8 weeks of open-
label lithium treatment during which intensive sampling for pharmacokinetic analyses 
occurred, followed by a 16-week open-label, post-acute stabilization phase22 for a total pre-
randomization lithium treatment period of 24 weeks.
The remaining 10 participants entered from CoLT 2 following an eight-week double-blind, 
placebo-controlled study22,30 in which participants were either treated with: (a) eight weeks 
of double-blind lithium which was followed by 16 weeks of open-label lithium prior to 
randomization, or (b) eight weeks of double-blind placebo followed by 24 weeks of open 
label lithium prior to randomization (see Figure 1).
The Discontinuation Trial was 28 weeks long. Study visits occurred at the following time 
points: Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, and 28 / end of treatment (EOT).
Participants
Briefly, eligible study participants were between the ages of 7 and 17 years (inclusive) and 
met diagnostic criteria for BP-I, manic or mixed. Further, study participants were required to 
be in good physical health, and be capable of swallowing study medication (lithium 
carbonate capsules) whole. For a complete listing of the inclusion/exclusion criteria for 
CoLT 1 and CoLT 2, as well as flow charts outlining study participant disposition through 
both trials, please see Findling et al. 30
In both CoLT 1 and CoLT 2, in order to be eligible for this Discontinuation Trial, the 
outpatient participant must have completed at least six of the last eight consecutive weeks 
(starting at Week 8) of post-acute open-label treatment with a Young Mania Rating Scale 
(YMRS) < 10 and Children’s Depression Rating Scale-Revised (CDRS-R) < 35,31,32 and a 
therapeutic lithium level (≥ 0.6 mEq/L). Psychotherapy was allowed during post-acute open-
label treatment, and must have been of stable intensity for the last four weeks of the post-
acute open-label period prior to entry into the Discontinuation Trial.
Diagnostic Procedures
Eligible study participants underwent a psychiatric interview with a board-certified or board-
eligible child and adolescent psychiatrist to establish a clinical diagnosis of BP-I-manic or 
mixed phase prior to receiving any study-related medication. Additionally, subjects and their 
parents or guardians were assessed by an interviewer trained on study-specific procedures 
using the Schedule for Affective Disorders and Schizophrenia for School Aged Children-
Present and Lifetime Version (K-SADS-PL) 33 to confirm the clinician’s diagnosis.
Findling et al. Page 4
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2020 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Outcome Measures
At each visit, psychometric outcome measures including the YMRS, CDRS-R, Clinical 
Global Impressions-Severity (CGI-S),34 and CGI-I were obtained. In addition, completed at 
baseline and Weeks 4, 8, 16, and 28/EOT were the Children’s Global Assessment Scale 
(CGAS),35 and the Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M).36 
Inter-rater reliability was established and maintained with quarterly assessments across 
investigative sites for the YMRS and CDRS-R.
Safety Assessments
Side effects were assessed at every study visit by direct, open-ended query of the 
participants and guardians with ascertainment facilitated using the Side Effects Form for 
Children and Adolescents (SEFCA),37 supplemented by specific items from the UKU Side 
Effect Rating Scale38 and the Safety Monitoring and Uniform Report Form (SMURF).39 
Neurological side effects were assessed using the Neurological Examination for Lithium 
(NELi) 30 and the Neurological Rating Scale (NRS).40 The adverse events reported in the 
results are a summation of all ascertained events, regardless of methodology, that were 
determined by the study team to be adverse events.
Blood pressure, pulse, and weight were measured at each study visit. Comprehensive 
physical examinations, including measurement of height and an electrocardiogram (ECG) 
were performed at baseline and EOT.
A fasting comprehensive chemistry profile, complete blood count with differential, lipid 
profile, thyroid profile, urinalysis, and urine toxicology screen were performed at baseline 
and EOT. These assessments were also performed, non-fasting, at Weeks 8, 16, and 20 
(CoLT 1). To monitor renal function, creatinine clearance was measured at baseline and 
Weeks 16 (CoLT 2) and 28/EOT. Females of childbearing potential received a urine and 
serum pregnancy test at baseline and Weeks 8, 16, 20 (CoLT 1) and 28/EOT.
Randomization
Using a blinded random assignment and blinded placebo-controlled discontinuation design, 
approximately half of the responders remained on maintenance lithium treatment and the 
other half underwent gradual taper of their lithium dose by the substitution of identically 
appearing placebo capsules for active lithium capsules. The randomization was stratified by 
age group, stimulant treatment, antipsychotic medication use and gender.
Lithium Dosing
Participants’ lithium treatment was optimized during the antecedent Long-Term 
Effectiveness Phase. The dose was maintained by an unblinded physician in order to sustain 
a recommended trough level between 0.8 and 1.2 mEq/L, unless side effects precluded this 
level. The maximum level after which dose increases were not permitted was 1.4 mEq/L. 
Dosing was flexible, and it was based upon the achievement of the target serum level, 
apparent benefit, and apparent tolerability. Dose reductions or increases could be made at 
any time as clinically indicated. To accurately assess trough levels, lithium serum 
concentration was obtained after a minimum of seven days after a dose change.
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In CoLT 1,22 the Long-Term Effectiveness Phase followed the open-label eight-week 
pharmacokinetic treatment phase whereas in CoLT 2, it followed the eight-week double-
blind placebo-controlled acute efficacy study. Participants who received placebo during the 
Efficacy Phase had their doses titrated by unblinded study physicians via weekly lithium 
dose adjustments to maximize efficacy and minimize adverse events. As in CoLT 1, lithium 
dose was maintained in order to sustain a recommended trough level between 0.8 and 1.2 
mEq/L whilst not exceeding 1.4 mEq/L.
Concomitant medication treatment could be initiated prior to entry into this Discontinuation 
Trial following a standardized algorithm,22 based on the extant evidence-based literature at 
the time these series of studies were designed. Briefly, the algorithm included a sequence of 
medications to treat residual symptoms of psychosis, mania and hypomania, depression, 
anxiety, and attention-deficit/hyperactivity disorder (ADHD), prioritized in that order and 
based upon study participant need. To be eligible for entry into this concomitant treatment 
algorithm, the participant’s lithium dose and mood symptoms needed to be stable. No dose 
changes to adjunctive medications or new adjunctive medications were to be prescribed in 
the Discontinuation Trial. For additional details, please see Findling et al.22
For participants randomized to receive placebo in the Discontinuation Trial., a gradual 
medication taper was begun. Dependent upon the participant’s lithium dose at the end of the 
Long-Term Effectiveness phase, the daily dosage was gradually reduced by 300 mg or 600 
mg increments each week over the course of four weeks.
For those assigned to continue lithium, their lithium dose was not changed, if possible, 
during this double-blind period as the patient’s lithium dose had previously been optimized. 
However, based on efficacy and tolerability, a participant’s lithium dose could be adjusted 
within a range recommended by the blinded study doctor. The maximum daily dose was not 
to exceed 40 mg/kg. In addition, an un-blinded physician at each site monitored the serum 
lithium level for all study participants, regardless of randomization assignment. The un-
blinded physician ensured that lithium levels were maintained at the requisite therapeutic 
levels for participants randomized to remain on lithium treatment, between 0.8 and 1.2 
mEq/L.
Discontinuation Criteria
Participants were withdrawn from the double-blind Discontinuation Trial and could have 
been eligible for subsequent open-label treatment based on any of the following criteria:
(1) study physician discretion; (2) persistent moderate symptoms of depression (assessed by 
the administration of the CDRS-R) and/or mania (as assessed by the administration of the 
YMRS) defined by 10 points above the baseline (last visit in the Long-Term Effectiveness 
Phase) for two consecutive visits, including interim visits, separated by at least 14 days; (3) 
any of the following symptoms rated at the maximum score for any of the following YMRS 
items: #2 (continuous hyperactivity-cannot be calmed), #7 (incoherent; communication 
impossible), #8 (delusions, hallucinations), or #9 (assaultive; destructive); (4) development 
of a syndromal manic, mixed or depressive episode, according to DSM-IV in the treating 
physician’s opinion; (5) persistent significant exacerbation of symptoms based on having a 
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CGI-I score indicative of the participant being “much worse” or “very much worse” for two 
consecutive visits in the Discontinuation Trial, including interim visits, separated by at least 
14 days as compared to the final open label treatment assessment.
Statistical Methods
The primary endpoint is the relative risk of discontinuation for any reason, comparing 
lithium to placebo. Time from randomization to discontinuation for any reason was analyzed 
using Cox proportional hazards regression models. Participants who did not discontinue 
were censored at the time of the Week 28 visit. The Cox proportional hazards regression 
model included treatment group as the independent factor and was stratified by age group. 
The data are shown graphically using Kaplan-Meier estimates. The analyses are based on the 
as-treated (AT) population.
Owing to a miscommunication from the coordinating center, three participants from CoLT 1 
who were randomized to receive placebo received lithium, instead. Since these three 
participants received lithium for the entire course of the discontinuation study, had the 
integrity of their blinded treatment maintained, and received blinded treatment identical to 
other participants who received lithium, they are being reported and analyzed within the 
lithium group.
In addition to time to discontinuation for any reason, time to recurrence of mood symptoms 
also was analyzed using Cox proportional hazards regression models with treatment group 
as the independent factor and stratified by age strata. Participants with recurrence of mood 
symptoms are considered to have had an intervention if they received concomitant 
psychotherapy, concomitant psychotropic medications or if they left the Discontinuation 
Trial at the time of the recurrence of mood symptoms. Participants were considered to have 
recurrence of mood symptoms at the time of the intervention and participants not having 
recurrence of mood symptoms were censored when they left the Discontinuation trial. One 
participant had a recurrence of mood episode at Week 2 but had no interventions and 
completed all 28 weeks of the Discontinuation Trial. This participant was censored at Week 
28 for this analysis.
For those who were discontinued due to mood symptomatology, failure for meeting 
remission criteria was based on previously-described thresholds for depressive41 and 
manic22 symptomatology. Patients’ qualitative mood state at relapse was based on the 
presence of manic, depressive or mixed (both manic and depressive symptomatology) 
features at either the last patient visit or at the last patient visit where suprathreshold 
symptomatology was manifest.
Continuous secondary endpoints were analyzed using a linear regression model with the 
change score as the dependent variable, baseline score as a covariate, and age strata, gender, 
study (CoLT 1 vs. CoLT 2) and AT treatment group as factors. Endpoints analyzed were 
YMRS total score CDRS-R, CGAS and PGBI-10M.
Comparison of categorical baseline variables between treatment groups was made using the 
Chi-square statistic and continuous variables were compared using Kruskal-Wallis Chi-
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square statistic. The baseline value is from the last day of the previous phase, last 
observation carried forward (LOCF). The change score is the difference between the LOCF 
value and baseline value. All statistical analysis was performed by using the SAS System for 
Windows, Version 9.2 or higher (SAS Institute, Cary, NC).
Results
Patient Disposition and Demographics
Participant disposition for the Discontinuation Trial is summarized in Figure 1. Enrollment 
into the trials occurred from December 2006 through April 2009 (CoLT 1) and May 2010 
through March 2013 (CoLT 2). For the purposes of this manuscript, analysis of the 
Discontinuation Trial includes 31 participants: 21 participants from the CoLT 1 study and 10 
participants from the CoLT 2 study. There were 17 participants who received lithium and 14 
participants who received placebo.
Of the 31 Discontinuation Trial participants, 13 (42%) completed all 28 weeks of the 
Discontinuation Trial: 11 (65%) lithium and 2 (14%) placebo-treated patients. The 
remaining 18 (58%) participants discontinued during the discontinuation trial (see Figure 1). 
Most of the participants (n=13; 72%) discontinued due to emergence of mood symptoms 
that met or exceeded pre-specified thresholds: lithium treated patients - 3 (17.6%) and 
placebo-treated patients - 10 (71.4 %). These patients came disproportionately from the 
placebo-treated group. Five discontinued for reasons other than mood symptoms: 3 (17.6%) 
in the lithium group and 2 (14.3 %) in the placebo group. These non-mood related 
discontinuations occurred at similar rates across both treatment groups.
Demographic information is summarized in Table 1. Prior to entry into the Discontinuation 
Trial, nine of the participants (29%) were prescribed concomitant psychostimulants for 
ADHD symptoms. Five (16%) were prescribed an additional mood stabilizer and six (19%) 
were prescribed an adjunctive antipsychotic medication. At the end of the Long-Term 
Effectiveness Phase (baseline), YMRS, CDRS-R, CGAS, and PGBI-10M scores did not 
significantly differ among those participants who received lithium compared with those who 
received placebo.
Dosing
Participants treated with lithium started the Discontinuation Trial at a mean (SD) dose of 
1394 (424) mg/day / 30.7 (5.1) mg/kg/day. The mean (SD) dose of placebo-treated patients 
at the beginning of the Discontinuation Trial was 1736 (529) mg/day / 28.1 (6.3) mg/kg/day. 
Based upon Kruskal-Wallis p-values, there were no between-group differences with regard 
to starting lithium dose [dose (mg/day): p=0.064; weight-based dose (mg/kg/day): p=0.250]. 
The mean (SD) last reported dose of lithium at the end of the phase was 1412 (438) mg/day / 
29.8 (7.2) mg/kg/day.
Efficacy
Efficacy data are outlined in Table 2. The results of Cox regression analysis of the primary 
efficacy endpoint found a statistically significant difference, with the participants receiving 
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lithium having a lower HR compared to participant receiving placebo: HR=0.28 (compared 
to placebo), 95% CI 0.10 – 0.78, and p=0.015 after adjustment by age strata (Figure 2).
Discontinuation due to mood symptoms occurred in 5/17 (29%) of participants treated with 
lithium compared to 10/14 (71%) of participants treated with placebo, HR-0.24 (lithium 
compared to placebo), 95% CI 0.08 – 0.74 (p=0.013) after adjustment by age strata. Of the 
five patients who were discontinued during lithium treatment, three had manic 
symptomatology and two had elevations in both manic and depressive (i.e. mixed) 
symptoms. Half of the 10 placebo-treated patients who were discontinued had manic 
symptoms and the other half had mixed features at discontinuation.
The participants receiving lithium completed an average of 20.7 weeks (SD 11.2 weeks), 
compared to those participants receiving placebo, who completed an average of 8.7 weeks 
(SD 8.5 weeks). The difference in the length of participation between the two treatment 
groups was statistically significant (p=0.043).
On the secondary outcome measures participants who were maintained on lithium tended to 
have better outcomes across all measures. The mean (SD) change in symptom severity from 
baseline as measured by change in YMRS score was 4.9 (9.6) for participants treated with 
lithium and 10.1 (10.0) for participants treated with placebo (p=0.053). See Table S1, 
available online.
For CDRS-R score mean (SD) change from baseline to LOCF was 1.7 (5.9) for lithium 
treated participants and 5.2 (10.9) for placebo treated participants (p=0.159). See Table S2, 
available online. The mean (SD) change of the CGAS score was −0.5 (18.9) for lithium 
treated participants and −10.3 (12.7) for placebo treated participants (p=0.005). The mean 
(SD) of change from baseline to LOCF in the parent-rated total PGBI-10M score was 1.2 
(7.5) for participants treated with lithium and 5.6 (8.5) for participants treated with placebo 
(p=0.078).
Adverse Events
Adverse event (AE) data are presented in Table 3. Most AEs were mild to moderate in 
severity. Twenty-four (77 %) of the study participants experienced at least one adverse event 
during this trial. Of the 17 lithium treated participants, 15 (88%) reported at least one AE; of 
the 14 placebo treated participants, nine (64%) reported at least one AE.
The most frequent AEs for those participants who received lithium were: headache (35%), 
upper abdominal pain (29%), enuresis (24%), vomiting (24%), initial insomnia (18%), upper 
respiratory tract infection (18%), decreased appetite (12%) and nasopharyngitis (12%). For 
participants who received placebo, the most frequent AEs were: headache (29%), initial 
insomnia (14%) and decreased appetite (14%).
Of note, increased suicidal ideation was not reported as an AE. There were no deaths or 
completed suicides. There was one serious AE, aggression, which led to a lithium-treated 
participant’s study discontinuation. The event (reported on study day 18) was moderate in 
severity and rated as possibly related to study medication.
Findling et al. Page 9
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2020 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
There was no statistically significant between-group difference with respect to weight gain. 
A mean (SD) weight gain of 1.8 (3.5) kg was seen in the lithium-treated participants and a 
mean (SD) weight gain of 1.7 (4.1) kg was observed in placebo-treated participants. The 
mean (SD) change in weight Z score for lithium treated participants was −0.03 (0.28) and 
for placebo treated participants was 0.04 (0.14).
Clinical Laboratory Evaluations
The thyroid stimulating hormone decreased 2.9 (2.4) mIU/L in placebo treated participants 
from the start of the study to LOCF, with a smaller decrease of 0.6 (1.6) mIU/L in the 
participants that remained on lithium.
For lithium-treated patients, the mean (SD) white blood count (WBC) was 7.3 (2.1) × 103/L 
and 8.5 (2.1) × 103/L for participants treated with placebo at the beginning of the trial. At 
study’s end the WBC was 8.3 (2.2) × 103/L for lithium participants and 7.1 (1.3) for 
participants treated with placebo (using LOCF).
The mean (SD) estimated creatinine clearance at the beginning of the trial for study 
participants treated with lithium was 135 (36) mL/min and 124 (28) mL/min for study 
participants treated with placebo. At the end of the phase, the mean estimated creatinine 
clearance for study participants treated with lithium was 128 (24) mL/min and 123 (25) 
mL/min for study participants treated with placebo. The mean creatinine concentration was 
0.6 (0.1) mg/dL at both baseline and LOCF for lithium treated participants. The placebo 
group had mean (SD) creatinine measurement of 0.7 (0.1) mg/dL at baseline and a mean of 
0.7 (0.1) mg/dL at LOCF.
Safety
No participants discontinued as a result of any clinically significant findings on vital signs, 
physical examination or electrocardiographic findings.
Discussion
This randomized, blinded, placebo-controlled discontinuation trial supports a role for 
lithium as a maintenance treatment in pediatric patients with bipolar disorder. These data 
contribute to the extant medical literature, as little double-blind data for maintenance 
treatments exists in this population.
The adverse effect profile was consistent with what has been previously reported both in 
adults and in our previous work.21 Of note, lithium was not associated with weight gain or 
concomitant metabolic effects compared to placebo. This observation distinguishes lithium 
from the antipsychotic agents10-13,15 which, prior to this study, is the only class of 
medications with evidence of acute efficacy but with a risk of substantial weight gain and 
metabolic disturbances. Renal function was closely monitored throughout the study, and no 
significant changes in creatinine clearance or renal function were found. Also, of note, 
patients did not experience an increase in thyroid stimulating hormone, a side effect 
associated with lithium in 42 the acute phase of the CoLT 2 study, but TSH decreased in 
placebo-treated patients.21
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The primary strength of this multi-site trial is the placebo-controlled design and the 
corresponding gradual tapering of lithium prior to discontinuation in the placebo group. 
Studies in adult patients have found that mood symptoms tend to emerge and increase in 
severity soon after rapid discontinuation of lithium treatment, compared to a more delayed 
tendency toward recurrence when lithium is slowly tapered.43,44
The relatively small sample size and trial duration are limitations of the current trial. The 
sample size is commensurate with the unique challenges of enrolling and maintaining 
acutely manic patients in placebo-controlled studies on an outpatient basis. In addition, the 
multi-phase “stepped” design of the CoLT studies required that participants complete the 
previous two study phases before entering this Discontinuation trial.
Most of our sample (67.7%) came from CoLT 1 which had only open-label phases prior to 
this study. To enter from CoLT 2, participants needed to complete all 8 weeks of the 
placebo-controlled acute efficacy study before being enrolled in the open-label Long Term 
Effectiveness phase. Furthermore, the criteria for stability in the LTE phase prior to entering 
the Discontinuation phase were quite stringent. Not surprisingly for this population, many 
LTE participants did not attain durable stability and therefore, did not meet the entry criteria 
for this study phase.
This randomized, blinded, placebo-controlled discontinuation trial builds support for the use 
of lithium in the maintenance treatment of pediatric bipolar I disorder. Lithium treatment for 
the study duration demonstrated good tolerability. However, efficacy and safety over a 
longer period of time is an empiric question that remains unanswered in this patient 
population. Therefore, additional longer and larger studies that can more definitively 
evaluate the efficacy of lithium for the long-term treatment of pediatric bipolar disorder are 
needed.
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Figure 1: 
Participant Disposition As Treated – Discontinuation Trial
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Figure 2. 
Risk of Discontinuation for Any Reason (As Treated)
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Table 1
Baseline Demographics
Treatment Received
Characteristic Lithium
(n=17)
Placebo
(n=14)
Total
(N=31)
Age at baseline, years Mean (SD) 11.3 (2.2) 12.9 (2.5) 12.0 (2.5)
Gender n (%)
Male 12 (71%) 9 (64%) 21 (58%)
Female 5 (29%) 5 (36%) 10 (32%)
Race n (%)
Caucasian 16 (94%) 9 (64%) 25 (81%)
African American 1 (6%) 4 (29%) 5 (16%)
≥ one Race 0 (0%) 1 (7%) 1 (3%)
YMRS Total Score Mean (SD) 4.8 (3.1) 5.9 (2.5) 5.3 (2.8)
CDRS-R Total Score Mean (SD) 20.2 (3.4) 22.4 (6.1) 21.2 (4.9)
CGAS Score Mean (SD) 74.8 (12.5) 71.5 (14.2) 73.3 (13.2)
PGBI-10M Score Mean (SD) 5.1 (4.1) 5.7 (6.9) 5.4 (5.5)
Comorbid Diagnoses
ADHD 12 (71%) 10 (71%) 22 (71%)
Disruptive Behavior Disorder 2 (12%) 2 (14%% 4 (13%)
Anxiety Disorder 2 (12%) 4 (29%) 6 (19%)
Enuresis 1 (6%) 0 (0%) 1 (3%)
Weight, kg Mean (SD) 45.7 (12.0) 65.7 (27.2) 54.7 (22.3)
Weight Z Score Mean (SD) 0.70 (0.99) 1.32 (1.20) 0.98 (1.12)
Concomitant Medicationsa
Aripiprazole 0 (0%) 1 (7%) 1 (3%)
Atomoxetine 1 (6%) 0 (0%) 1 (3%)
Guanfacine 0 (0%) 1 (7%) 1 (3%)
Hydroxyzineb 3 (18%) 3 (21%) 6 (19%)
Lamotrigine 0 (0%) 1 (7%) 1 (3%)
Methylphenidate 0 (0%) 1 (7%) 1 (3%)
Mixed Amphetamine Salts 3 (18%) 2 (14%) 5 (16%)
Quetiapine 1 (6%) 3 (21%) 4 (13%)
Risperidone 2 (12%) 3 (21%) 5 (16%)
Valproate 0 (0%) 1 (7%) 1 (3%)
Concomitant Psychotherapy n (%) 5 (29.4%) 6 (42.9%) 11 (35.5%)
NOTE: For comorbid diagnoses and concomitant psychotropic medications, p-values were not calculated due to small cell size. ADHD = attention-
deficit/hyperactivity disorder; CDRS-R = Children’s Depression Rating Scale-Revised; YMRS = Young Mania Rating Scale.
a
Patients could have received more than one concomitant psychotropic medication.
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b
During this study, either lorazepam or hydroxyzine could be prescribed by the treating physician as a rescue medication for sleeplessness and 
agitation.
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2020 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Findling et al. Page 19
Table 2
Risk of Discontinuation for Any Reason
Treatment Received Group
Lithium
(n=17)
Placebo
(n=14)
Participants Status during Discontinuation Trial
 Discontinued 3 (17.6%) 2 (14.3%)
 Completed Study 11 (64.7%) 2 (14.3%)
 Mood Relapse and Entered Restabilization Phase 3 (17.6%) 10 (71.4%)
Number of Participants
 Completed trial 11 (64.7%) 2 (14.3%)
 Discontinued (failed) 6 (35.3%) 12 (85.7%)
 Hazard Ratio (Relative to Placebo) 0.28
 (95% CI) (0.10, 0.78)
 P 0.0150
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Table 3:
Overall Tolerability and Most Frequently Cccurring Adverse Events (In ≥ 10% of the Total Population)
Discontinuation Phase
Treatment Received
Lithium
(n = 17)
Placebo
(n = 14)
Total
(N = 31)
Number of AEs 102 25 127
Number of Participants with at Least One AE p > 0.05 15 (88%) 9 (64%) 24 (77%)
Average number of AEs per Participant 6.0 1.8 4.1
Number of SAEs 1 (6%) 0 (0%) 1 (3%)
Highest Severity per Participant
 No reported AEs 2 (12%) 5 (36%) 7 (23%)
 Mild 10 (59%) 5 (36%) 15 (48%)
 Moderate 3 (18%) 4 (29%) 7 (23%)
 Severe 2 (12%) 0 (0%) 2 (6%)
System Organ Class
Preferred Term
Nervous system disorders
 Headache 6 (35%) 4 (29%) 10 (32%)
Gastrointestinal disorders
 Abdominal pain upper 5 (29%) 1 (7%) 6 (19%)
Psychiatric disorders
 Initial insomnia 3 (18%) 2 (14%) 5 (16%)
Renal and urinary disorders
 Enuresis 4 (24%) 0 (0%) 4 (13%)
Gastrointestinal disorders
 Vomiting 4 (24%) 0 (0%) 4 (13%)
Metabolism and nutrition disorders
 Decreased appetite 2 (12%) 2 (14%) 4 (13%)
Infections and infestations
 Nasopharyngitis 2 (12%) 1 (7%) 3 (10%)
 Upper respiratory tract infection 3 (18%) 0 (0%) 3 (10%)
Note: AE = adverse event; SAE = serious adverse event
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2020 February 01.
